Merck (MRK) Invested Capital (2009 - 2026)

Merck has disclosed Invested Capital across 18 years of filings, most recently posting $48.3 billion for Q1 2026.

• In Q1 2026, Invested Capital fell 2.89% year-over-year to $48.3 billion; the TTM figure through Mar 2026 stood at $48.3 billion (down 2.89% YoY), while the FY2025 annual figure was $55.3 billion, up 12.71% from the prior year.
• Invested Capital slipped to $48.3 billion in Q1 2026, from $55.3 billion in the prior quarter.
• Over the last five years, Invested Capital for MRK reached as high as $55.3 billion in Q4 2025 and fell as low as $39.0 billion in Q4 2023.
• The 5-year median for Invested Capital is $47.7 billion (2024), against an average of $47.0 billion.
• Annual changes were most pronounced in 2022 — Invested Capital grew 29.05% — and 2023, when it slipped 18.74%.
• A 5-year view of Invested Capital shows it stood at $48.0 billion in 2022, then fell by 18.74% to $39.0 billion in 2023, then increased by 25.67% to $49.0 billion in 2024, then gained by 12.71% to $55.3 billion in 2025, then slipped by 12.54% to $48.3 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $48.3 billion, $55.3 billion, and $53.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.